NASDAQ:LBPH Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis → A.I. is a Tidal Wave - Here’s What to Buy (From Chaikin Analytics) (Ad) Free LBPH Stock Alerts $22.45 +0.49 (+2.23%) (As of 09:33 AM ET) Add Compare Share Share Today's Range$22.04▼$22.4550-Day Range$17.00▼$23.9452-Week Range$3.60▼$28.15Volume2,150 shsAverage Volume1.23 million shsMarket Capitalization$808.65 millionP/E RatioN/ADividend YieldN/APrice Target$43.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Longboard Pharmaceuticals alerts: Email Address Longboard Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside97.3% Upside$43.33 Price TargetShort InterestBearish14.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.88Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.01) to ($2.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector416th out of 924 stocksPharmaceutical Preparations Industry183rd out of 428 stocks 4.5 Analyst's Opinion Consensus RatingLongboard Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongboard Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted14.81% of the float of Longboard Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLongboard Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.Change versus previous monthShort interest in Longboard Pharmaceuticals has recently decreased by 0.61%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLongboard Pharmaceuticals does not currently pay a dividend.Dividend GrowthLongboard Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LBPH. Previous Next 2.7 News and Social Media Coverage News SentimentLongboard Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Longboard Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for LBPH on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Longboard Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.64% of the stock of Longboard Pharmaceuticals is held by insiders.Percentage Held by Institutions63.28% of the stock of Longboard Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Longboard Pharmaceuticals are expected to decrease in the coming year, from ($2.01) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longboard Pharmaceuticals is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longboard Pharmaceuticals is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongboard Pharmaceuticals has a P/B Ratio of 13.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarAI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Longboard Pharmaceuticals Stock (NASDAQ:LBPH)Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.Read More LBPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LBPH Stock News HeadlinesApril 17, 2024 | markets.businessinsider.comBexicaserin’s Promising Future: Buy Rating Justified by Strong Clinical Data and Potential Blockbuster StatusApril 3, 2024 | businesswire.comLongboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15May 2, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.April 2, 2024 | businesswire.comLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)March 27, 2024 | finance.yahoo.comLongboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%March 16, 2024 | finance.yahoo.comLBPH Apr 2024 17.500 putMarch 14, 2024 | finance.yahoo.comLongboard Pharmaceuticals Inc Reports Full Year 2023 Financial ResultsMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed: Longboard Pharmaceuticals’ Bexicaserin Shows Promising Efficacy and Strategic MilestonesMay 2, 2024 | Chaikin Analytics (Ad)A.I. is a Tidal Wave - Here’s What to BuyThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.March 12, 2024 | benzinga.comRecap: Longboard Pharmaceuticals Q4 EarningsMarch 12, 2024 | businesswire.comLongboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 3, 2024 | finance.yahoo.comLBPH May 2024 30.000 callMarch 1, 2024 | businesswire.comLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)February 24, 2024 | finance.yahoo.comLBPH Mar 2024 22.500 callFebruary 24, 2024 | finance.yahoo.comLBPH Aug 2024 15.000 putFebruary 22, 2024 | benzinga.comLongboard Pharmaceuticals Stock (NASDAQ:LBPH), Short Interest ReportFebruary 21, 2024 | finance.yahoo.comLongboard Pharmaceuticals, Inc. (LBPH)February 16, 2024 | msn.comLongboard stock up 8% as Citi initiates at buy, citing takeover potentialFebruary 5, 2024 | ca.finance.yahoo.comLBPH Feb 2024 30.000 callFebruary 2, 2024 | finance.yahoo.comLongboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)February 1, 2024 | finance.yahoo.comLongboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in FebruaryJanuary 26, 2024 | msn.comTCBP and PCSA among pre-market losersJanuary 17, 2024 | fool.comForget the "Magnificent Seven" -- This Stock Has Nearly Quadrupled in 2024, and Wall Street Thinks It Can Go a Lot HigherJanuary 16, 2024 | markets.businessinsider.comCantor Fitzgerald Maintains Overweight Rating for Longboard Pharmaceuticals: Here's What You Need To KnowJanuary 12, 2024 | realmoney.thestreet.comLongboard Pharmaceuticals price target raised by $17 at B. Riley, here's whyJanuary 8, 2024 | tmcnet.comLongboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesJanuary 8, 2024 | finance.yahoo.comLongboard Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesSee More Headlines Receive LBPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/01/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LBPH CUSIPN/A CIK1832168 Webwww.longboardpharma.com Phone619-592-9775FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$43.33 High Stock Price Target$60.00 Low Stock Price Target$32.00 Potential Upside/Downside+104.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.53% Return on Assets-85.21% Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio5.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book13.15Miscellaneous Outstanding Shares36,017,000Free Float34,346,000Market Cap$790.93 million OptionableOptionable Beta1.24 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Kevin R. Lind (Age 48)President, CEO, Secretary & Director Comp: $1.07MMs. Brandi L. Roberts CPA (Age 50)M.B.A., Executive VP & CFO Comp: $662.65kDr. Randall E. Kaye M.D. (Age 62)Executive VP & Chief Medical Officer Comp: $717.95kMr. Chadwick J. Orevillo MPHExecutive VP & Head of OperationsMegan E. KnightVP & Head of Investor RelationsMr. Steven W. Spector J.D. (Age 59)Executive VP, Head of Business Development & General Counsel Dr. Anne M. Danks Ph.D.VP & Head of Nonclinical Research & DevelopmentMr. Gus CardenasVP & Head of Quality AssuranceDr. Marco Peters Ph.D.VP & Head of Translational ScienceDr. Dewey McLin Ph.D.VP & Head of Medical AffairsMore ExecutivesKey CompetitorsPureTech HealthNASDAQ:PRTCZentalis PharmaceuticalsNASDAQ:ZNTLAurinia PharmaceuticalsNASDAQ:AUPHOcular TherapeutixNASDAQ:OCULArcutis BiotherapeuticsNASDAQ:ARQTView All CompetitorsInsiders & InstitutionsDenali Advisors LLCBought 9,300 shares on 4/19/2024Ownership: 0.026%Parkman Healthcare Partners LLCBought 73,935 shares on 2/15/2024Ownership: 1.802%Platinum Investment Management Ltd.Bought 127,048 shares on 2/14/2024Ownership: 0.532%CIBC Asset Management IncBought 67,607 shares on 2/13/2024Ownership: 0.889%Arena Pharmaceuticals IncSold 3,978,540 sharesTotal: $96.48 M ($24.25/share)View All Insider TransactionsView All Institutional Transactions LBPH Stock Analysis - Frequently Asked Questions Should I buy or sell Longboard Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LBPH shares. View LBPH analyst ratings or view top-rated stocks. What is Longboard Pharmaceuticals' stock price target for 2024? 6 Wall Street research analysts have issued 12-month price targets for Longboard Pharmaceuticals' stock. Their LBPH share price targets range from $32.00 to $60.00. On average, they anticipate the company's stock price to reach $43.33 in the next twelve months. This suggests a possible upside of 97.3% from the stock's current price. View analysts price targets for LBPH or view top-rated stocks among Wall Street analysts. How have LBPH shares performed in 2024? Longboard Pharmaceuticals' stock was trading at $6.03 on January 1st, 2024. Since then, LBPH shares have increased by 264.2% and is now trading at $21.96. View the best growth stocks for 2024 here. Are investors shorting Longboard Pharmaceuticals? Longboard Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,950,000 shares, an increase of 32.4% from the March 15th total of 3,740,000 shares. Based on an average daily trading volume, of 644,800 shares, the days-to-cover ratio is currently 7.7 days. Currently, 14.9% of the shares of the stock are sold short. View Longboard Pharmaceuticals' Short Interest. When is Longboard Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our LBPH earnings forecast. How were Longboard Pharmaceuticals' earnings last quarter? Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) issued its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.02. What ETFs hold Longboard Pharmaceuticals' stock? ETFs with the largest weight of Longboard Pharmaceuticals (NASDAQ:LBPH) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and iShares Neuroscience and Healthcare ETF (IBRN).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). When did Longboard Pharmaceuticals IPO? Longboard Pharmaceuticals (LBPH) raised $75 million in an IPO on Friday, March 12th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO. Who are Longboard Pharmaceuticals' major shareholders? Longboard Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Denali Advisors LLC (0.03%). View institutional ownership trends. How do I buy shares of Longboard Pharmaceuticals? Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LBPH) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldAI finds its first serious applicationWall Street StarHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsYour bank is lying to you.MyBankTrackerDollar CancelledLear CapitalUrgent Alert: Is the U.S. Implementing a Digital Dollar?Gold Gate Capital Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longboard Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
